Like many organisations, we use technology on our website to collect information that helps us enhance the experience of our site. The cookies we use allow our website to work and help us to better understand what information is most useful to you.
|Name of Notice||Financial Markets Conduct (Haleon plc) Exemption Notice 2022|
|Gazette Notification Date||2022-05-30|
|Date In Force||2022-05-30|
|Act||Financial Markets Conduct|
The Financial Markets Conduct (Haleon plc) Exemption Notice 2022 exempts GlaxoSmithKline plc (GSK) and Haleon plc (Haleon) from the obligations in Part 3 (Disclosure of offers of financial products) of the Financial Markets Conduct Act 2013. The exemption is in relation to a demerger to be effected by an indirect in-specie distribution of ordinary shares in Haleon to GSK shareholders, including shareholders in New Zealand. The exemption is subject to conditions that are similar to the class exemption known as the Financial Markets Conduct (Incidental Offers) Exemption Notice 2021 modified to reflect the transaction structure.